Summit Therapeutics PLC (SMMT) Trading Up 16.6%
Shares of Summit Therapeutics PLC (NASDAQ:SMMT) were up 16.6% on Monday . The company traded as high as $7.00 and last traded at $6.94, with a volume of 65,194 shares. The stock had previously closed at $5.95.
A number of analysts have recently weighed in on SMMT shares. Canaccord Genuity reiterated a “buy” rating on shares of Summit Therapeutics PLC in a report on Thursday, June 16th. Zacks Investment Research upgraded shares of Summit Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Wednesday, August 3rd. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Summit Therapeutics PLC in a report on Thursday, June 16th. Janney Montgomery Scott started coverage on shares of Summit Therapeutics PLC in a report on Tuesday, June 21st. They set a “buy” rating for the company. Finally, HC Wainwright started coverage on shares of Summit Therapeutics PLC in a report on Friday, September 16th. They set a “buy” rating and a $26.00 target price for the company. Six analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $19.40.
The stock has a 50-day moving average price of $6.72 and a 200-day moving average price of $7.50. The company’s market capitalization is $87.90 million.
A hedge fund recently bought a new stake in Summit Therapeutics PLC stock. Granite Point Capital Management L.P. purchased a new position in shares of Summit Therapeutics PLC (NASDAQ:SMMT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 112,676 shares of the company’s stock, valued at approximately $891,000. Granite Point Capital Management L.P. owned approximately 0.92% of Summit Therapeutics PLC at the end of the most recent quarter.
About Summit Therapeutics PLC
Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.